RDY vs. TEVA, RXDX, JAZZ, KRTX, APLS, UTHR, ROIV, LEGN, VTRS, and CTLT
Should you be buying Dr. Reddy's Laboratories stock or one of its competitors? The main competitors of Dr. Reddy's Laboratories include Teva Pharmaceutical Industries (TEVA), Prometheus Biosciences (RXDX), Jazz Pharmaceuticals (JAZZ), Karuna Therapeutics (KRTX), Apellis Pharmaceuticals (APLS), United Therapeutics (UTHR), Roivant Sciences (ROIV), Legend Biotech (LEGN), Viatris (VTRS), and Catalent (CTLT). These companies are all part of the "pharmaceutical preparations" industry.
Dr. Reddy's Laboratories vs.
Teva Pharmaceutical Industries (NYSE:TEVA) and Dr. Reddy's Laboratories (NYSE:RDY) are both mid-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their earnings, analyst recommendations, risk, institutional ownership, media sentiment, valuation, dividends, community ranking and profitability.
Dr. Reddy's Laboratories has a net margin of 18.38% compared to Teva Pharmaceutical Industries' net margin of -10.73%. Teva Pharmaceutical Industries' return on equity of 27.58% beat Dr. Reddy's Laboratories' return on equity.
Dr. Reddy's Laboratories has lower revenue, but higher earnings than Teva Pharmaceutical Industries. Teva Pharmaceutical Industries is trading at a lower price-to-earnings ratio than Dr. Reddy's Laboratories, indicating that it is currently the more affordable of the two stocks.
Teva Pharmaceutical Industries has a beta of 1.19, indicating that its share price is 19% more volatile than the S&P 500. Comparatively, Dr. Reddy's Laboratories has a beta of 0.49, indicating that its share price is 51% less volatile than the S&P 500.
Teva Pharmaceutical Industries received 998 more outperform votes than Dr. Reddy's Laboratories when rated by MarketBeat users. Likewise, 67.59% of users gave Teva Pharmaceutical Industries an outperform vote while only 58.33% of users gave Dr. Reddy's Laboratories an outperform vote.
Teva Pharmaceutical Industries currently has a consensus target price of $10.67, indicating a potential upside of 43.18%. Dr. Reddy's Laboratories has a consensus target price of $67.00, indicating a potential upside of 22.94%. Given Teva Pharmaceutical Industries' higher possible upside, analysts clearly believe Teva Pharmaceutical Industries is more favorable than Dr. Reddy's Laboratories.
In the previous week, Dr. Reddy's Laboratories had 1 more articles in the media than Teva Pharmaceutical Industries. MarketBeat recorded 10 mentions for Dr. Reddy's Laboratories and 9 mentions for Teva Pharmaceutical Industries. Teva Pharmaceutical Industries' average media sentiment score of 0.30 beat Dr. Reddy's Laboratories' score of 0.02 indicating that Teva Pharmaceutical Industries is being referred to more favorably in the media.
50.4% of Teva Pharmaceutical Industries shares are held by institutional investors. Comparatively, 9.8% of Dr. Reddy's Laboratories shares are held by institutional investors. 0.8% of Teva Pharmaceutical Industries shares are held by company insiders. Comparatively, 2.0% of Dr. Reddy's Laboratories shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
Summary
Teva Pharmaceutical Industries beats Dr. Reddy's Laboratories on 9 of the 17 factors compared between the two stocks.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding RDY and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Dr. Reddy's Laboratories Competitors List
Related Companies and Tools
